Chimerix Inc (CMRX) 40.16 $CMRX
Chimerix Presents Update on Preliminary Data From AdVise Study of Brincidofovir for Adenovirus Infection at BMT Tandem Meetings
GlobeNewswire - Thu Feb 12, 7:01AM CST
Chimerix, Inc. (Nasdaq:CMRX) announced the presentation of preliminary data from the open-label, Phase 3 AdVise trial of brincidofovir for adenovirus infection showing a short-term mortality rate of less than 40 percent. The current analysis is based on the first 85 subjects enrolled and supports the trend seen in the first 48 subjects as presented at the meeting of the Infectious Diseases Society of America (IDSA), IDWeek. Historic mortality rates as high as 80 percent for disseminated adenovirus disease have been reported. These data will be presented today at 4:45 p.m. PT at the 2015 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplantation, taking place in San Diego, CA. Final trial results will be reported at a later date and will comprise clinical outcomes for trial subjects as compared to matched historical controls.
CMRX: 40.16 (+0.08)
ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
PR Newswire - Wed Feb 04, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, "Nucleoside Phosphonate Salts." The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031.
CMRX: 40.16 (+0.08)
Chimerix Focusing Efforts on CMV and Adenovirus Pivotal Trials
GlobeNewswire - Fri Jan 30, 5:12PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
CMRX: 40.16 (+0.08)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034
GlobeNewswire - Mon Jan 12, 8:15AM CST
- Opportunity to pursue multiple additional indications for brincidofovir
CMRX: 40.16 (+0.08)
Cramer: A Toast to Beer Companies Benefiting From Lower Oil Prices
at The Street - Thu Jan 08, 10:27AM CST
Constellation Brands is among the companies getting a sales boost from the drop in oil prices, Cramer says. But is it time to finally buy energy stocks?
CMRX: 40.16 (+0.08), CHK: 21.08 (+0.58), STZ: 113.03 (-0.48), MRO: 29.49 (+0.71), OAS: 16.84 (-0.03), APC: 89.44 (+2.13)
Chimerix Provides Update on Brincidofovir Pivotal Phase 3 AdVise Trial for the Treatment of Adenovirus
GlobeNewswire - Thu Jan 08, 7:50AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided an update on AdVise, a Phase 3 trial of brincidofovir for the treatment of adenovirus, an infection that can be fatal in people with weakened immune systems. There are currently no approved treatments for adenovirus.
CMRX: 40.16 (+0.08)
Chimerix to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:30AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 10:00 am PST (1:00 pm EST) at the Westin Saint Francis Hotel in San Francisco.
CMRX: 40.16 (+0.08), JPM: 59.67 (+0.10)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 40.16 (+0.08), SWKS: 81.85 (-0.57), IBM: 160.40 (+1.88), CHL: 68.70 (-0.22), HZNP: 16.84 (-0.41), TKMR: 21.45 (-0.22), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), PLNR: 6.63 (-0.07), AVGO: 110.15 (+0.45), RFMD: 16.59 (-0.35)
Chimerix Provides Recap of 2014 Events
GlobeNewswire - Tue Dec 23, 7:37AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir.
CMRX: 40.16 (+0.08)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 40.16 (+0.08), GILD: 101.90 (+1.10)
Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 40.16 (+0.08), PTCT: 53.37 (-0.74)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
Chimerix Presents Update on Preliminary Data From AdVise Study of Brincidofovir for Adenovirus Infection at BMT Tandem Meetings
GlobeNewswire - Thu Feb 12, 7:01AM CST
Chimerix, Inc. (Nasdaq:CMRX) announced the presentation of preliminary data from the open-label, Phase 3 AdVise trial of brincidofovir for adenovirus infection showing a short-term mortality rate of less than 40 percent. The current analysis is based on the first 85 subjects enrolled and supports the trend seen in the first 48 subjects as presented at the meeting of the Infectious Diseases Society of America (IDSA), IDWeek. Historic mortality rates as high as 80 percent for disseminated adenovirus disease have been reported. These data will be presented today at 4:45 p.m. PT at the 2015 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplantation, taking place in San Diego, CA. Final trial results will be reported at a later date and will comprise clinical outcomes for trial subjects as compared to matched historical controls.
CMRX: 40.16 (+0.08)
ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
PR Newswire - Wed Feb 04, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, "Nucleoside Phosphonate Salts." The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread®), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031.
CMRX: 40.16 (+0.08)
Chimerix Focusing Efforts on CMV and Adenovirus Pivotal Trials
GlobeNewswire - Fri Jan 30, 5:12PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
CMRX: 40.16 (+0.08)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034
GlobeNewswire - Mon Jan 12, 8:15AM CST
- Opportunity to pursue multiple additional indications for brincidofovir
CMRX: 40.16 (+0.08)
Cramer: A Toast to Beer Companies Benefiting From Lower Oil Prices
at The Street - Thu Jan 08, 10:27AM CST
Constellation Brands is among the companies getting a sales boost from the drop in oil prices, Cramer says. But is it time to finally buy energy stocks?
CMRX: 40.16 (+0.08), CHK: 21.08 (+0.58), STZ: 113.03 (-0.48), MRO: 29.49 (+0.71), OAS: 16.84 (-0.03), APC: 89.44 (+2.13)
Chimerix Provides Update on Brincidofovir Pivotal Phase 3 AdVise Trial for the Treatment of Adenovirus
GlobeNewswire - Thu Jan 08, 7:50AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided an update on AdVise, a Phase 3 trial of brincidofovir for the treatment of adenovirus, an infection that can be fatal in people with weakened immune systems. There are currently no approved treatments for adenovirus.
CMRX: 40.16 (+0.08)
Chimerix to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 07, 7:30AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 10:00 am PST (1:00 pm EST) at the Westin Saint Francis Hotel in San Francisco.
CMRX: 40.16 (+0.08), JPM: 59.67 (+0.10)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 40.16 (+0.08), SWKS: 81.85 (-0.57), IBM: 160.40 (+1.88), CHL: 68.70 (-0.22), HZNP: 16.84 (-0.41), TKMR: 21.45 (-0.22), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), PLNR: 6.63 (-0.07), AVGO: 110.15 (+0.45), RFMD: 16.59 (-0.35)
Chimerix Provides Recap of 2014 Events
GlobeNewswire - Tue Dec 23, 7:37AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir.
CMRX: 40.16 (+0.08)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST
CMRX: 40.16 (+0.08), GILD: 101.90 (+1.10)
Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 40.16 (+0.08), PTCT: 53.37 (-0.74)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
